07.25.22
OmniActive Health Technologies’ curcumin extract Curcuwin Ultra+ was linked in a recent study to joint health and mobility benefits, which the company expects will be published later this year.
The present study was a prospective, randomized, double-blind, parallel, placebo-controlled study involving 135 subjects with mild knee osteoarthritis. They received 250 mg of the supplement, standardized to contain 50 mg of curcuminoids, or a 500 mg dose of the formula, which contains 100 mg of curcuminoids for 84 days. Both doses of Curcuwin Ultra+ resulted in early onset efficacy, as early as day five, for overall joint health comfort and mobility, according to OmniActive.
“The results of this robust study demonstrated that a low dose of just 250 mg of Curcuwin Ultra+ may serve as a unique nutritional solution for managing issues related to knee joint comfort and mobility including cartilage health,” said Deshanie Rai, PhD, FACN, VP, global scientific and regulatory affairs at OmniActive, said.
Earlier this year, a pharmacokinetic study published in Advances in Therapy demonstrated that a 250 mg dose of Curcuwin Ultra+ was 144-times more bioavailable and absorbed 40% faster than a standard curcumin extract used in comparison.
“The combined findings demonstrate that with Curcuwin Ultra+, less is more. We are thrilled with the results, this is groundbreaking for the curcumin market.”
The present study was a prospective, randomized, double-blind, parallel, placebo-controlled study involving 135 subjects with mild knee osteoarthritis. They received 250 mg of the supplement, standardized to contain 50 mg of curcuminoids, or a 500 mg dose of the formula, which contains 100 mg of curcuminoids for 84 days. Both doses of Curcuwin Ultra+ resulted in early onset efficacy, as early as day five, for overall joint health comfort and mobility, according to OmniActive.
“The results of this robust study demonstrated that a low dose of just 250 mg of Curcuwin Ultra+ may serve as a unique nutritional solution for managing issues related to knee joint comfort and mobility including cartilage health,” said Deshanie Rai, PhD, FACN, VP, global scientific and regulatory affairs at OmniActive, said.
Earlier this year, a pharmacokinetic study published in Advances in Therapy demonstrated that a 250 mg dose of Curcuwin Ultra+ was 144-times more bioavailable and absorbed 40% faster than a standard curcumin extract used in comparison.
“The combined findings demonstrate that with Curcuwin Ultra+, less is more. We are thrilled with the results, this is groundbreaking for the curcumin market.”
